ライフサイエンスコーパス: pseudotyping

1 ssed by vesicular stomatitis virus G-protein pseudotyping.

2 sion and encapsidation, and envelope protein pseudotyping.

3 teins were screened for efficient FIV vector pseudotyping and hepatocyte transduction.

4 e kinetics of thymic infection, modulated by pseudotyping and viral interference, facilitates a stepw

5 airs to NAb in donor plasma by using a virus pseudotyping assay, thereby providing an ideal setting t

6 e chimeric Envs were evaluated using a virus-pseudotyping assay.

7 Pseudotyping by the glycoprotein of vesicular stomatitis

8 Truncation of the gp41 tail, or pseudotyping by vesicular stomatitis virus glycoprotein,

9 Pseudotyping by VSV-G markedly suppressed the requiremen

10 es and thymomas suggested that the change in pseudotyping characteristics was not the result of the e

11 Additional experiments indicated that pseudotyping contributed to the elevated polytropic viru

12 or localization and innate activation, fiber pseudotyping did not significantly change the outcome of

13 e molecules varies, depending on the type of pseudotyping envelope proteins.

14 ed a single-cycle form of HIV-1, prepared by pseudotyping envelope-defective HIV-1 plasmids with the

15 ant virions; similar results are obtained in pseudotyping experiments using wild-type or truncated HI

16 ines in vitro in co-culture, infectivity and pseudotyping experiments.

17 ed virus with natural lung tropism; however, pseudotyping feline immunodeficiency virus (FIV)-based l

18 Pseudotyping FIV with GP64 from three species of baculov

19 Conversely, pseudotyping FIV with the envelope protein from influenz

20 of marker genes; control of synaptic spread; pseudotyping for infection of selected cells; addition o

21 onnative viral particles in a process termed pseudotyping; however, the molecular mechanisms governin

22 h amplification on complementing cell lines, pseudotyping if desired, purification by ultracentrifuga

23 This shows the potential of pseudotyping in expanding the utility of lentiviral vect

24 Finally, these studies indicate that pseudotyping in the HIV-1 virion-based fusion assay may

25 xed retroviral infections frequently exhibit pseudotyping, in which the genome of one virus is packag

26 Having determined that this pseudotyping increased the efficiency of gene transfer t

27 Virus pseudotyping is a useful and safe technique for studying

28 Although pseudotyping is widely used for engineering chimeric vir

29 However, this process, termed pseudotyping, is poorly understood at the molecular leve

30 did not exhibit a comparable high titer upon pseudotyping, it led to a significant increase in distal

31 rodent fibroblasts but are still capable of pseudotyping lentiviral and oncoretroviral vectors.

32 ght be suitable as alternatives to VSV-G for pseudotyping lentivirus vectors.

33 Thus, pseudotyping might account for the PERV transmission pre

34 ic stage, a dramatic change in the extent of pseudotyping occurred in thymuses.

35 We suggest that pseudotyping occurs through specific lipid-protein inter

36 n of mice with an ecotropic virus results in pseudotyping of intact endogenous viruses that have not

37 However, this transmission was due to the pseudotyping of PERV-C (a virus without human tropism) b

38 We have previously demonstrated that pseudotyping of the nonprimate equine infectious anemia

39 Furthermore, pseudotyping of the polytropic MuLV genome within ecotro

40 Marked amplification and pseudotyping of the polytropic MuLV were also observed i

41 This process of complementation, known as pseudotyping, often can occur even when the glycoprotein

42 LVs in coinfected mice may be facilitated by pseudotyping or, alternatively, by transactivation of th

43 We conclude that pseudotyping provides a useful means to manipulate viral

44 investigated the possibility of "genetically pseudotyping" replication-competent MLV by replacing the

45 inding and fusion to CD13 is a candidate for pseudotyping retroviral envelopes or modifying other vir

46 Pseudotyping retrovirus and lentivirus vectors with diff

47 Pseudotyping SIVmac/HIV-1 overcame this deficiency, sugg

48 We used a pseudotyping strategy to investigate the cell biology of

49 n antifiloviral screening system, based on a pseudotyping strategy, and its application in the discov

50 Using this pseudotyping strategy, the involvement of the ubiquitin-

51 Using pseudotyping strategy, we produced double-stranded (dsAA

52 Pseudotyping studies show that the differential tissue t

53 The HSV pseudotyping system established in this study presents a

54 ur knowledge, this is the first time the VSV pseudotyping system has been successfully extended beyon

55 This HSV pseudotyping system pioneered in this work opens doors f

56 The AcMNPV pseudotyping system provides an efficient and powerful m

57 e using a human immunodeficiency virus-based pseudotyping system to identify specific regions that af

58 We have used the pseudotyping system to study the tropism of viruses bear

59 try by using a recently developed retroviral pseudotyping system.

60 affect host cell properties and recombinant pseudotyping systems in which filovirus structural glyco

61 Current retroviral pseudotyping systems using the HTLV-1 envelope generate

62 se modified retroviral vectors and the VSV-G pseudotyping technique constitute significant improvemen

63 the potential benefits which may arise from pseudotyping the HIV-1 lentiviral vector with its homolo

64 DC-directed specificity is achieved through pseudotyping the vector with an engineered Sindbis virus

65 Despite this, mixed infections lead to pseudotyping, the association of the viral cores of one

66 ses from cDNA, amplification of the viruses, pseudotyping them with EnvA or EnvB and concentration an

67 ein (Ebo-GP), we have developed a system for pseudotyping these glycoproteins into murine leukemia vi

68 This defect can be rescued by pseudotyping these mutant viruses with vesicular stomati

69 We suggest that these two regions dictate pseudotyping through interactions with specific lipid en

70 Using pseudotyping to assess Env function in single-round infe

71 We describe here an improved system for pseudotyping using a defective human immunodeficiency vi

72 truncating the gp41 cytoplasmic domain or by pseudotyping viruses with the glycoprotein of vesicular

73 In this report, we describe pseudotyping which occurred among the polytropic and eco

74 zation in vitro can be partially bypassed by pseudotyping with Ad45 fiber protein, indicating that a

75 of CyPA-deficient virions is not restored by pseudotyping with Env of amphotropic murine leukemia vir

76 rions and that this block can be reversed by pseudotyping with heterologous retroviral envelope glyco

77 ly developed targeting lentiviral vectors by pseudotyping with modified Sindbis virus envelope protei

78 nd confocal microscopy, we demonstrated that pseudotyping with rabies virus envelope glycoprotein (RV

79 rotrophin receptor), thus demonstrating that pseudotyping with RV-G targets lentiviral vectors for tr

80 In vivo, lentiVLP pseudotyping with the gp160 envelope or with a combinati

81 Remarkably, pseudotyping with the HAdV-5 fiber and/or penton RGD loo

82 , transient HIV-1 expression system based on pseudotyping with the vesicular stomatitis virus glycopr

83 Pseudotyping with the vesicular stomatitus virus G (VSV-

84 importance of high titer retroviral vectors, pseudotyping with VSV-G protein, and in situ selection.

85 f complete endogenous retrovirus genomes via pseudotyping within exogenous retroviral virions.